Anti-TSLP antibody constructs and their uses
By developing an antibody construct that specifically recognizes TSLP, the interaction between TSLP and TSLPR and IL-7Rα is completely blocked, solving the problem that existing antibodies cannot completely block TSLP signaling and achieving more effective treatment for inflammatory diseases such as asthma.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- PROTEOLOGIX US INC
- Filing Date
- 2024-08-23
- Publication Date
- 2026-05-26
AI Technical Summary
Existing anti-TSLP antibodies, such as tazebrutinib (Tezspire™), can only partially block TSLP signaling and cannot completely inhibit the interaction between TSLP and TSLPR and IL-7Rα, resulting in limited therapeutic effects on inflammatory diseases such as asthma.
An antibody construct containing specific recognition of TSLP, including specific heavy and light chain variable regions, was developed. This construct can completely block the interaction of TSLP with TSLPR and IL-7Rα, enhance the blocking ability of TSLP signaling, and has cross-reactivity with human and cynomolgus monkey TSLP.
It achieves complete blockade of TSLP signaling, significantly reduces the secretion of pro-inflammatory cytokines by immune cells, provides stronger therapeutic effects, and has a significant improvement in the treatment of inflammatory diseases such as asthma.
Smart Images
Figure CN122094979A_ABST